Global Stem Cell And Applications Market Set To Grow To $25.1bn By 2023

02 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Stem Cell Technologies and Applications Market 2018-2018: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications

Visiongain believes that the next ten years in the stem cell market will see many crucial breakthroughs, including: multiple approvals, particularly in the cardiovascular segment but increasingly also in the CNS segment; increased use and clinical validation of hESCs and iPSCs; and major changes in the drug development process, enabled by new stem cell-based assays.

The lead analyst of the report commented “Advances in related areas of regenerative medicine, such as tissue engineering, bioprinting and biomaterials, could interact with stem cell development to generate new opportunities to treat disease. Organ regeneration would be a high priority for companies in this area; tissue engineering of a thymus using stem cells is an example. 3D printing could be used to form scaffolds and tissues for orthopaedic conditions and wound healing.

New technologies will be needed to ensure that scaling-up of manufacturing operations can be done effectively once stem cell treatments enter the market. Scalability is often cited as one of the major barriers in translating promising pre-clinical and clinical-stage results into a valid and commercially viable therapy.”

Leading companies featured in the report include Mesoblast, Pharmicell, NuVasive, Orthofix, MEDIPOST, Reliance Life Sciences, Gamida Cell, Neuralstrem, ReNeuron, Apceth, Novartis, TiGenix, Ocata Therapeutics, Athersys.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever